<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Atomic &#8211; Grupo TTD</title>
	<atom:link href="https://grupottd.org/tag/atomic/feed/" rel="self" type="application/rss+xml" />
	<link>https://grupottd.org</link>
	<description>Grupo de Tratamiento de los Tumores Digestivos</description>
	<lastBuildDate>Tue, 23 Jun 2026 08:49:35 +0000</lastBuildDate>
	<language>es</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.5</generator>

<image>
	<url>https://grupottd.org/wp-content/uploads/2026/03/cropped-Logo-TTD-favicon-32x32.png</url>
	<title>Atomic &#8211; Grupo TTD</title>
	<link>https://grupottd.org</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Atezolizumab más FOLFOX para tumores colon E.III dMMR</title>
		<link>https://grupottd.org/atezolizumab-mas-folfox-para-tumores-colon-e-iii-dmmr/</link>
					<comments>https://grupottd.org/atezolizumab-mas-folfox-para-tumores-colon-e-iii-dmmr/#respond</comments>
		
		<dc:creator><![CDATA[Susana Rodríguez]]></dc:creator>
		<pubDate>Tue, 23 Jun 2026 08:49:13 +0000</pubDate>
				<category><![CDATA[Artículos comentados]]></category>
		<category><![CDATA[adyuvancia]]></category>
		<category><![CDATA[atezolizumab]]></category>
		<category><![CDATA[Atomic]]></category>
		<category><![CDATA[CCR]]></category>
		<category><![CDATA[DMMR]]></category>
		<category><![CDATA[Estadio III]]></category>
		<category><![CDATA[FOLFOX]]></category>
		<category><![CDATA[nuevo estándar]]></category>
		<category><![CDATA[supervivencia libre recaída]]></category>
		<guid isPermaLink="false">https://grupottd.org/?p=13331</guid>

					<description><![CDATA[La adición de atezolizumab a mFOLFOX6 en cáncer de colon estadio III dMMR mejoró de forma significativa la supervivencia libre de enfermedad (86,3% vs. 76,2% a 3 años; HR 0,50). El beneficio fue mayor en quienes recibieron >6 ciclos de quimioterapia. La toxicidad grado 3–4 aumentó (84% vs. 72%), especialmente la no hematológica. No se observaron diferencias en supervivencia global.

CONCLUSIONES: 
•  Atezolizumab+mFOLFOX6 mejora la SLE a 3 años (86,3% vs. 76,2%).
•  Reduce riesgo de recaída o muerte (HR 0,50).
•  Mayor beneficio en >6 ciclos de quimioterapia.
•  Aumentan toxicidades grado 3–4.
•  Sin diferencia significativa en SG.
]]></description>
			<style id="elementor-post-13331">.elementor-13331 .elementor-element.elementor-element-3ce7a18b{--display:flex;--padding-top:0px;--padding-bottom:0px;--padding-left:0px;--padding-right:0px;}.elementor-13331 .elementor-element.elementor-element-658f317a > .elementor-widget-container{padding:0px 0px 20px 0px;}.elementor-13331 .elementor-element.elementor-element-4a299971{--display:flex;--flex-direction:column;--container-widget-width:100%;--container-widget-height:initial;--container-widget-flex-grow:0;--container-widget-align-self:initial;--flex-wrap-mobile:wrap;--gap:20px 40px;--row-gap:20px;--column-gap:40px;border-style:none;--border-style:none;--margin-top:0px;--margin-bottom:20px;--margin-left:0px;--margin-right:0px;--padding-top:20px;--padding-bottom:20px;--padding-left:30px;--padding-right:30px;}.elementor-13331 .elementor-element.elementor-element-4a299971:not(.elementor-motion-effects-element-type-background), .elementor-13331 .elementor-element.elementor-element-4a299971 > .elementor-motion-effects-container > .elementor-motion-effects-layer{background-color:#7A7A7A0D;}.elementor-13331 .elementor-element.elementor-element-2264f626{--display:flex;--justify-content:flex-start;--gap:5px 0px;--row-gap:5px;--column-gap:0px;--padding-top:0px;--padding-bottom:0px;--padding-left:0px;--padding-right:0px;}.elementor-13331 .elementor-element.elementor-element-571428a8{--display:flex;--flex-direction:row;--container-widget-width:calc( ( 1 - var( --container-widget-flex-grow ) ) * 100% );--container-widget-height:100%;--container-widget-flex-grow:1;--container-widget-align-self:stretch;--flex-wrap-mobile:wrap;--align-items:center;--gap:4px 8px;--row-gap:4px;--column-gap:8px;--padding-top:0px;--padding-bottom:0px;--padding-left:0px;--padding-right:0px;}.elementor-13331 .elementor-element.elementor-element-c9b8ac6 .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );color:var( --e-global-color-accent );}.elementor-13331 .elementor-element.elementor-element-522b0f51 .elementor-heading-title{font-size:var( --e-global-typography-a7220b8-font-size );font-weight:var( --e-global-typography-a7220b8-font-weight );line-height:var( --e-global-typography-a7220b8-line-height );color:#646464;}.elementor-13331 .elementor-element.elementor-element-241536ae{--display:flex;--flex-direction:row;--container-widget-width:calc( ( 1 - var( --container-widget-flex-grow ) ) * 100% );--container-widget-height:100%;--container-widget-flex-grow:1;--container-widget-align-self:stretch;--flex-wrap-mobile:wrap;--align-items:center;--gap:4px 8px;--row-gap:4px;--column-gap:8px;--padding-top:0px;--padding-bottom:0px;--padding-left:0px;--padding-right:0px;}.elementor-13331 .elementor-element.elementor-element-148cd8bf .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );color:var( --e-global-color-accent );}.elementor-13331 .elementor-element.elementor-element-2294010a .elementor-heading-title{font-size:var( --e-global-typography-a7220b8-font-size );font-weight:var( --e-global-typography-a7220b8-font-weight );line-height:var( --e-global-typography-a7220b8-line-height );color:#646464;}.elementor-13331 .elementor-element.elementor-element-392a579f{--display:flex;--flex-direction:row;--container-widget-width:calc( ( 1 - var( --container-widget-flex-grow ) ) * 100% );--container-widget-height:100%;--container-widget-flex-grow:1;--container-widget-align-self:stretch;--flex-wrap-mobile:wrap;--align-items:center;--gap:4px 8px;--row-gap:4px;--column-gap:8px;--flex-wrap:wrap;--padding-top:0px;--padding-bottom:0px;--padding-left:0px;--padding-right:0px;}.elementor-13331 .elementor-element.elementor-element-31655606 .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );color:var( --e-global-color-accent );}.elementor-13331 .elementor-element.elementor-element-34dd77b0 .elementor-heading-title{font-size:14px;font-weight:400;line-height:1.4em;color:#646464;}.elementor-13331 .elementor-element.elementor-element-4e9ff277{--display:flex;--flex-direction:row;--container-widget-width:calc( ( 1 - var( --container-widget-flex-grow ) ) * 100% );--container-widget-height:100%;--container-widget-flex-grow:1;--container-widget-align-self:stretch;--flex-wrap-mobile:wrap;--align-items:center;--gap:4px 8px;--row-gap:4px;--column-gap:8px;--flex-wrap:wrap;--padding-top:0px;--padding-bottom:0px;--padding-left:0px;--padding-right:0px;}.elementor-13331 .elementor-element.elementor-element-8521b33 .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );color:var( --e-global-color-accent );}.elementor-13331 .elementor-element.elementor-element-5bb74bd8 .elementor-heading-title{font-size:14px;font-weight:400;line-height:1.4em;color:#646464;}.elementor-13331 .elementor-element.elementor-element-67254483{--display:flex;--padding-top:0px;--padding-bottom:0px;--padding-left:0px;--padding-right:0px;}.elementor-13331 .elementor-element.elementor-element-33cb564e{--display:flex;--margin-top:20px;--margin-bottom:0px;--margin-left:0px;--margin-right:0px;--padding-top:0px;--padding-bottom:0px;--padding-left:0px;--padding-right:0px;}.elementor-13331 .elementor-element.elementor-element-4679cddc .elementor-button{background-color:var( --e-global-color-9f14806 );font-weight:500;fill:var( --e-global-color-primary );color:var( --e-global-color-primary );border-style:solid;border-width:1px 1px 1px 1px;}.elementor-13331 .elementor-element.elementor-element-4679cddc .elementor-button:hover, .elementor-13331 .elementor-element.elementor-element-4679cddc .elementor-button:focus{background-color:var( --e-global-color-primary );color:var( --e-global-color-9f14806 );}.elementor-13331 .elementor-element.elementor-element-4679cddc .elementor-button:hover svg, .elementor-13331 .elementor-element.elementor-element-4679cddc .elementor-button:focus svg{fill:var( --e-global-color-9f14806 );}.elementor-13331 .elementor-element.elementor-element-41955f1d .elementor-button{background-color:var( --e-global-color-9f14806 );font-weight:500;fill:var( --e-global-color-primary );color:var( --e-global-color-primary );border-style:solid;border-width:1px 1px 1px 1px;}.elementor-13331 .elementor-element.elementor-element-41955f1d .elementor-button:hover, .elementor-13331 .elementor-element.elementor-element-41955f1d .elementor-button:focus{background-color:var( --e-global-color-primary );color:var( --e-global-color-9f14806 );}.elementor-13331 .elementor-element.elementor-element-41955f1d .elementor-button:hover svg, .elementor-13331 .elementor-element.elementor-element-41955f1d .elementor-button:focus svg{fill:var( --e-global-color-9f14806 );}.elementor-13331 .elementor-element.elementor-element-67f1d66d{--display:flex;--flex-direction:row;--container-widget-width:calc( ( 1 - var( --container-widget-flex-grow ) ) * 100% );--container-widget-height:100%;--container-widget-flex-grow:1;--container-widget-align-self:stretch;--flex-wrap-mobile:wrap;--align-items:center;--gap:10px 10px;--row-gap:10px;--column-gap:10px;--padding-top:30px;--padding-bottom:0px;--padding-left:0px;--padding-right:0px;}.elementor-13331 .elementor-element.elementor-element-9c6d187 > .elementor-widget-container{padding:5px 5px 5px 5px;border-style:solid;border-width:1px 1px 1px 1px;border-color:#4747475E;border-radius:46px 46px 46px 46px;}.elementor-13331 .elementor-element.elementor-element-59554da0 .elementor-icon-box-wrapper{text-align:start;}.elementor-13331 .elementor-element.elementor-element-59554da0 .elementor-icon-box-title{margin-block-end:0px;}.elementor-13331 .elementor-element.elementor-element-59554da0 .elementor-icon-box-title, .elementor-13331 .elementor-element.elementor-element-59554da0 .elementor-icon-box-title a{font-size:13px;}.elementor-13331 .elementor-element.elementor-element-59554da0 .elementor-icon-box-description{font-size:14px;line-height:15px;}@media(max-width:1366px){.elementor-13331 .elementor-element.elementor-element-c9b8ac6 .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );}.elementor-13331 .elementor-element.elementor-element-522b0f51 .elementor-heading-title{font-size:var( --e-global-typography-a7220b8-font-size );line-height:var( --e-global-typography-a7220b8-line-height );}.elementor-13331 .elementor-element.elementor-element-148cd8bf .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );}.elementor-13331 .elementor-element.elementor-element-2294010a .elementor-heading-title{font-size:var( --e-global-typography-a7220b8-font-size );line-height:var( --e-global-typography-a7220b8-line-height );}.elementor-13331 .elementor-element.elementor-element-31655606 .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );}.elementor-13331 .elementor-element.elementor-element-8521b33 .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );}}@media(max-width:1200px){.elementor-13331 .elementor-element.elementor-element-571428a8{--flex-direction:row;--container-widget-width:initial;--container-widget-height:100%;--container-widget-flex-grow:1;--container-widget-align-self:stretch;--flex-wrap-mobile:wrap;--gap:0px 8px;--row-gap:0px;--column-gap:8px;--flex-wrap:wrap;}.elementor-13331 .elementor-element.elementor-element-241536ae{--flex-direction:row;--container-widget-width:initial;--container-widget-height:100%;--container-widget-flex-grow:1;--container-widget-align-self:stretch;--flex-wrap-mobile:wrap;--gap:0px 8px;--row-gap:0px;--column-gap:8px;--flex-wrap:wrap;}.elementor-13331 .elementor-element.elementor-element-392a579f{--flex-direction:row;--container-widget-width:initial;--container-widget-height:100%;--container-widget-flex-grow:1;--container-widget-align-self:stretch;--flex-wrap-mobile:wrap;--gap:0px 8px;--row-gap:0px;--column-gap:8px;--flex-wrap:wrap;}.elementor-13331 .elementor-element.elementor-element-4e9ff277{--flex-direction:row;--container-widget-width:initial;--container-widget-height:100%;--container-widget-flex-grow:1;--container-widget-align-self:stretch;--flex-wrap-mobile:wrap;--gap:0px 8px;--row-gap:0px;--column-gap:8px;--flex-wrap:wrap;}}@media(max-width:1024px){.elementor-13331 .elementor-element.elementor-element-c9b8ac6 .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );}.elementor-13331 .elementor-element.elementor-element-522b0f51 .elementor-heading-title{font-size:var( --e-global-typography-a7220b8-font-size );line-height:var( --e-global-typography-a7220b8-line-height );}.elementor-13331 .elementor-element.elementor-element-148cd8bf .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );}.elementor-13331 .elementor-element.elementor-element-2294010a .elementor-heading-title{font-size:var( --e-global-typography-a7220b8-font-size );line-height:var( --e-global-typography-a7220b8-line-height );}.elementor-13331 .elementor-element.elementor-element-31655606 .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );}.elementor-13331 .elementor-element.elementor-element-8521b33 .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );}}@media(max-width:767px){.elementor-13331 .elementor-element.elementor-element-c9b8ac6 .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );}.elementor-13331 .elementor-element.elementor-element-522b0f51 .elementor-heading-title{font-size:var( --e-global-typography-a7220b8-font-size );line-height:var( --e-global-typography-a7220b8-line-height );}.elementor-13331 .elementor-element.elementor-element-148cd8bf .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );}.elementor-13331 .elementor-element.elementor-element-2294010a .elementor-heading-title{font-size:var( --e-global-typography-a7220b8-font-size );line-height:var( --e-global-typography-a7220b8-line-height );}.elementor-13331 .elementor-element.elementor-element-31655606 .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );}.elementor-13331 .elementor-element.elementor-element-8521b33 .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );}}</style>							<content:encoded><![CDATA[		<div data-elementor-type="wp-post" data-elementor-id="13331" class="elementor elementor-13331" data-elementor-post-type="post">
				<div class="elementor-element elementor-element-3ce7a18b e-flex e-con-boxed e-con e-parent" data-id="3ce7a18b" data-element_type="container" data-e-type="container">
					<div class="e-con-inner">
				<div class="elementor-element elementor-element-658f317a elementor-widget elementor-widget-heading" data-id="658f317a" data-element_type="widget" data-e-type="widget" data-widget_type="heading.default">
				<div class="elementor-widget-container">
					<h2 class="elementor-heading-title elementor-size-default">Atezolizumab más FOLFOX para tumores colon E.III dMMR</h2>				</div>
				</div>
					</div>
				</div>
		<div class="elementor-element elementor-element-4a299971 e-con-full e-flex e-con e-child" data-id="4a299971" data-element_type="container" data-e-type="container" data-settings="{&quot;background_background&quot;:&quot;classic&quot;}">
		<div class="elementor-element elementor-element-2264f626 e-con-full e-flex e-con e-child" data-id="2264f626" data-element_type="container" data-e-type="container">
		<div class="elementor-element elementor-element-571428a8 e-con-full e-flex e-con e-child" data-id="571428a8" data-element_type="container" data-e-type="container">
				<div class="elementor-element elementor-element-c9b8ac6 elementor-widget elementor-widget-heading" data-id="c9b8ac6" data-element_type="widget" data-e-type="widget" data-widget_type="heading.default">
				<div class="elementor-widget-container">
					<h5 class="elementor-heading-title elementor-size-default">Edición:</h5>				</div>
				</div>
				<div class="elementor-element elementor-element-522b0f51 elementor-widget elementor-widget-heading" data-id="522b0f51" data-element_type="widget" data-e-type="widget" data-widget_type="heading.default">
				<div class="elementor-widget-container">
					<p class="elementor-heading-title elementor-size-default">Publicación científica 2026</p>				</div>
				</div>
				</div>
		<div class="elementor-element elementor-element-241536ae e-con-full e-flex e-con e-child" data-id="241536ae" data-element_type="container" data-e-type="container">
				<div class="elementor-element elementor-element-148cd8bf elementor-widget elementor-widget-heading" data-id="148cd8bf" data-element_type="widget" data-e-type="widget" data-widget_type="heading.default">
				<div class="elementor-widget-container">
					<h4 class="elementor-heading-title elementor-size-default">Fecha:</h4>				</div>
				</div>
				<div class="elementor-element elementor-element-2294010a elementor-widget elementor-widget-heading" data-id="2294010a" data-element_type="widget" data-e-type="widget" data-widget_type="heading.default">
				<div class="elementor-widget-container">
					<p class="elementor-heading-title elementor-size-default">23 de junio de 2026</p>				</div>
				</div>
				</div>
		<div class="elementor-element elementor-element-392a579f e-con-full e-flex e-con e-child" data-id="392a579f" data-element_type="container" data-e-type="container">
				<div class="elementor-element elementor-element-31655606 elementor-widget elementor-widget-heading" data-id="31655606" data-element_type="widget" data-e-type="widget" data-widget_type="heading.default">
				<div class="elementor-widget-container">
					<h4 class="elementor-heading-title elementor-size-default">Autores:</h4>				</div>
				</div>
				<div class="elementor-element elementor-element-34dd77b0 elementor-widget elementor-widget-heading" data-id="34dd77b0" data-element_type="widget" data-e-type="widget" data-widget_type="heading.default">
				<div class="elementor-widget-container">
					<p class="elementor-heading-title elementor-size-default">Sinicrope FA, Ou FS, Arnold D, Peters WR, Behrens RJ, Lieu CH, Matin K, Cohen DJ, Potter SL, Nixon AB, Kottschade LA, Kathol E, Frankel WL, Shergill A, Hsu D, Reinacher-Schick A, Mehan P, Gold PJ, Khalil MF, Zemla T, Gatten C, O'Reilly EM, Meyerhardt JA. </p>				</div>
				</div>
				</div>
		<div class="elementor-element elementor-element-4e9ff277 e-con-full e-flex e-con e-child" data-id="4e9ff277" data-element_type="container" data-e-type="container">
				<div class="elementor-element elementor-element-8521b33 elementor-widget elementor-widget-heading" data-id="8521b33" data-element_type="widget" data-e-type="widget" data-widget_type="heading.default">
				<div class="elementor-widget-container">
					<h4 class="elementor-heading-title elementor-size-default">Autora de la revisión:</h4>				</div>
				</div>
				<div class="elementor-element elementor-element-5bb74bd8 elementor-widget elementor-widget-heading" data-id="5bb74bd8" data-element_type="widget" data-e-type="widget" data-widget_type="heading.default">
				<div class="elementor-widget-container">
					<p class="elementor-heading-title elementor-size-default">Fernando Garicano. Hospital Universitario Galdakao-Usansolo (Miembro de la Asamblea General del Grupo TTD)</p>				</div>
				</div>
				</div>
				</div>
				</div>
		<div class="elementor-element elementor-element-67254483 e-flex e-con-boxed e-con e-parent" data-id="67254483" data-element_type="container" data-e-type="container">
					<div class="e-con-inner">
				<div class="elementor-element elementor-element-71cc5159 elementor-widget elementor-widget-text-editor" data-id="71cc5159" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p>La adición de atezolizumab a mFOLFOX6 en cáncer de colon estadio III dMMR mejoró de forma significativa la <strong>supervivencia libre de enfermedad</strong> (86,3% vs. 76,2% a 3 años; HR 0,50). El beneficio fue mayor en quienes recibieron &gt;6 ciclos de quimioterapia. La toxicidad grado 3–4 aumentó (84% vs. 72%), especialmente la no hematológica. No se observaron diferencias en supervivencia global.</p><p>CONCLUSIONES:</p><ul><li><strong>Atezolizumab+mFOLFOX6</strong> mejora la SLE a 3 años (86,3% vs. 76,2%).</li><li>Reduce riesgo de recaída o muerte (HR 0,50).</li><li>Mayor beneficio en &gt;6 ciclos de quimioterapia.</li><li>Aumentan toxicidades grado 3–4.</li><li>Sin diferencia significativa en SG.</li></ul>								</div>
				</div>
					</div>
				</div>
		<div class="elementor-element elementor-element-33cb564e e-flex e-con-boxed e-con e-parent" data-id="33cb564e" data-element_type="container" data-e-type="container">
					<div class="e-con-inner">
				<div class="elementor-element elementor-element-4679cddc elementor-align-center elementor-widget elementor-widget-button" data-id="4679cddc" data-element_type="widget" data-e-type="widget" data-widget_type="button.default">
				<div class="elementor-widget-container">
									<div class="elementor-button-wrapper">
					<a class="elementor-button elementor-button-link elementor-size-sm" href="https://grupottd.org/articulos-comentados/atezolizumab-plus-folfox-for-stage-iii-mismatch-repair-deficient-colon-cancer/">
						<span class="elementor-button-content-wrapper">
									<span class="elementor-button-text">Ver artículo comentado TTD completo</span>
					</span>
					</a>
				</div>
								</div>
				</div>
				<div class="elementor-element elementor-element-41955f1d elementor-align-center elementor-widget elementor-widget-button" data-id="41955f1d" data-element_type="widget" data-e-type="widget" data-widget_type="button.default">
				<div class="elementor-widget-container">
									<div class="elementor-button-wrapper">
					<a class="elementor-button elementor-button-link elementor-size-sm" href="https://pubmed.ncbi.nlm.nih.gov/41880612/" target="_blank">
						<span class="elementor-button-content-wrapper">
									<span class="elementor-button-text">Enlace al artículo original</span>
					</span>
					</a>
				</div>
								</div>
				</div>
					</div>
				</div>
		<div class="elementor-element elementor-element-67f1d66d e-con-full e-flex e-con e-child" data-id="67f1d66d" data-element_type="container" data-e-type="container">
				<div class="elementor-element elementor-element-9c6d187 elementor-widget elementor-widget-image" data-id="9c6d187" data-element_type="widget" data-e-type="widget" data-widget_type="image.default">
				<div class="elementor-widget-container">
															<img decoding="async" src="https://grupottd.org/wp-content/uploads/elementor/thumbs/fav_icon_TTD-r8xkio7ebt5062iunra09m8cc4544reqzr28q6uark.png" title="fav_icon_TTD" alt="fav_icon_TTD" loading="lazy" />															</div>
				</div>
				<div class="elementor-element elementor-element-59554da0 elementor-widget elementor-widget-icon-box" data-id="59554da0" data-element_type="widget" data-e-type="widget" data-widget_type="icon-box.default">
				<div class="elementor-widget-container">
							<div class="elementor-icon-box-wrapper">

			
						<div class="elementor-icon-box-content">

									<h3 class="elementor-icon-box-title">
						<span  >
							Publicado por:						</span>
					</h3>
				
									<p class="elementor-icon-box-description">
						Grupo TTD					</p>
				
			</div>
			
		</div>
						</div>
				</div>
				</div>
				</div>
		]]></content:encoded>
					
					<wfw:commentRss>https://grupottd.org/atezolizumab-mas-folfox-para-tumores-colon-e-iii-dmmr/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
	</channel>
</rss>
